Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

882269.pdf (1.61 MB)

Embargo

Item embargoed until 2026-11-30

Document type

Article

Version

Accepted version

Publication date

2025-12-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220812

Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1021/acsptsci.4c00629

Abstract

Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer’s disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays a pivotal role in neuroinflammation by hydrolyzing epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and neuroprotective properties, into pro-inflammatory dihydroepoxyeicosatrienoic acids (DHETs). Furthermore, the overexpression of the enzyme in the brains of AD patients and animal models of the disease highlights its relevance as a therapeutic target. Our previous studies, using the inhibitor UB-SCG-51 demonstrated that sEH inhibition regulates neuroinflammation and other mechanisms, such as the unfolded protein response pathway, while reducing autophagy, apoptosis, and neuronal death, thereby promoting neuroprotection. Building on these findings, we evaluated the arginine salt of the compound, designated UB-SCG-74, which offers improved oral absorption compared to that of UB-SCG-51 while retaining high permeability, potency, and selectivity. In experiments using 5XFAD mice, UB-SCG-74 treatment significantly improved cognition and synaptic plasticity, outperforming donepezil, a standard AD drug, and ibuprofen, an anti-inflammatory drug. Remarkably, these benefits persisted for 4 weeks after administration cessation, suggesting lasting therapeutic effects. Safety pharmacology studies showed no toxicity, supporting the advancement of UB-SCG-74 into preclinical regulatory evaluation. Our findings further indicate that sEH inhibition engages multiple neuroprotective pathways, potentially modifying both AD symptoms and disease progression, thus reinforcing its therapeutic potential.

Subject

Malalties neurodegeneratives, Epòxids, Malaltia de Parkinson

Subject (English)

Neurodegenerative Diseases, Epoxy compounds, Parkinson's disease

Citation

Collections

Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Citation

JARNE FERRER, Júlia, et al. Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies. ACS Pharmacology & Translational Science. 2025. Vol. 8, num. 2, pags. 533–542. ISSN 2575-9108. [consulted: 7 of August of 2026]. Available at: https://hdl.handle.net/2445/220812

Export metadata

JSON - METS

Share record